Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 3.85% and 4.34%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?